Pentoxifylline does not prevent neither liver damage nor early profibrogenic events in a rat model of non-alcoholic steatohepatitis

Pentoxifylline does not prevent neither liver damage nor early profibrogenic events in a rat model of non-alcoholic steatohepatitis

Background: Non-alcoholic steatohepatitis (NASH) is a metabolic disorder of the liver, which may evolve to fibrosis or cirrhosis. Pentoxifylline (PTX) has been postulated to act as an antifibrogenic agent able to inhibit hepatic stellate cell proliferation and collagen synthesis in vitro. Short-term...

Full description

Bibliographic Details
Main Authors: Paula Vial, Arnoldo Riquelme, Margarita Pizarro, Nancy Solís, Juan Andrés Madariaga, Gloria Aguayo, Ignacio Duarte, Alejandro Soza, Luigi Accatino, Marco Arrese
Format: Article
Language:English
Published: Elsevier 2006-01-01
Series:Annals of Hepatology
Subjects:
Steatohepatitis
pentoxifylline
fatty liver disease
liver fibrosis
choline-deficient diet
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119320356

Internet

http://www.sciencedirect.com/science/article/pii/S1665268119320356

Similar Items